Amerigo Scientific is proud to introduce a comprehensive suite of TACA-related antibody products designed to support researchers in their quest for more accurate, efficient, and effective cancer management strategies.
In general, abnormal glycosylation associated with cell carcinogenesis leads to the expression of TACAs. TACAs are considered to be crucial factors driving carcinogenic transformation. TACA has been reported to exist in a variety of malignant tumors, however, it is rarely found in normal tissues. Therefore, TACAs are attractive markers for distinguishing cancer cells from normal tissues. In addition, due to their tumor specificity, TACAs have gradually emerged as promising targets for the development of cancer immunotherapy.
TACAs are closely related to various behaviors of tumor cells, including cell growth, adhesion, proliferation, and migration. In addition, TACAs are also involved in the regulation of multiple cell pathways, such as apoptosis pathways, transmembrane receptor tyrosine kinase pathways, and angiogenesis pathways. Data show that TACAs also adhere through integrins, cadherins, and selectins.
Fig.1 Altered glycan expression occurs during tumor progression.1
TACAs are classified into five distinct categories based on structural characteristics. The first class is called the Globo series, such as Globo-H. The second type is called gangliosides, such as GD3 and GM2. Representatives of the third category are Lewis antigens, such as Lewis X, Lewis Y and sialyl Lewis X. The fourth category refers to truncated O-glycans, including Thomsennouveau (Tn) and Thomsen−Friendreich (TF). The fifth category is polysialic acid. TACAs are closely associated with tumor biology and, therefore, they are emerging as attractive targets for tumor therapy.
| Name | Classification | Related Cancers |
| Globo H | Globo Series | Breast, Ovary, Prostate, Lung, Colon |
| SSEA-3 | Globo Series | Breast, Colon |
| SSEA-4 | Globo Series | Breast, Glioblastoma, Prostate |
| GD2 | Gangliosides | Neuroblastoma, Melanoma, Breast |
| GD3 | Gangliosides | Neuroectodermal, Melanoma |
| Fuc-GM1 | Gangliosides | Small cell lung cancer |
| Lewis X | Lewis antigen | Hepatic, Bladder, Glioblastoma, Breast |
| Lewis Y | Lewis antigen | Hepatocellular, Ovarian |
| Tn | O-glycans | Ovarian, Breast, Prostate, Colon |
| TF | O-glycans | Ovarian, Prostate, Breast, Colon |
| Polysialic acid | Polysialylated | Breast, Glioblastoma |
TACAs are defined as representative cancer hallmarks that mediate important signaling effects in cancer biology. Therefore, TACAs have been proposed as a potential target for cancer diagnosis and therapy. Targeting tumor proliferation through anti-TACA therapy is a popular anticancer idea. In addition to monoclonal antibodies and vaccines, bispecific antibodies targeting TACAs have gradually received widespread attention.
Recognizing the unique needs of every research endeavor, we offer customized TACA-related antibody products for specific TACAs or novel targets. Our expert immunologists and biochemists collaborate closely with clients to design, produce, and validate custom antibodies, ensuring they meet the highest standards of quality and performance. For more information on TACAs and related products, please .
Reference
